J&J hands over $3.1M for .Baby; Pfizer announces promising Phase III data for Lyrica;

> Johnson & Johnson ($JNJ) shelled out $3.1 million in an auction for .Baby, beating out bidders such as Google ($GOOG). Story

> Pfizer ($PFE) reported promising Phase III clinical results for its nerve-pain treatment Lyrica (pregabalin). More (sub. req.)

> The FDA's Office of Prescription Drug Promotion is cracking down on one of Sunovion's print ads for seizure med Aptiom. Story (reg. req.)

> Starting in January, the Indian government will ban pharma companies from handing out freebies to doctors. More

> Apotex submitted an application to the FDA for a copycat version of Amgen's ($AMGN) $3.5 billion blockbuster Neulasta. Story (req. req.)

And Finally… The pharma industry is funneling money into veterinary education, with the world's leading animal drugmaker, Zoetis ($ZTS), awarding $3.6 million in scholarships over the past 5 years. More

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.